TES Pharma, a company that chief scientific advisor Roberto Pellicciari founded in 2010, aims to extend by a further 5 million euros the 10 million Series A round that launched earlier in April (see here a previous post by BeBeez). The company attracted the resources of Indaco Venture Partners while XGEN Venture and Foro delle Arti (Cucinelli Family) invested in the first tranche. Luca Benatti is the company’s ceo. TES will invest these resources in its pipeline of drugs development.
Angelini Ventures, the corporate venture arm of Angelini Industries, and Invivo Partners poured 20 million euros in Denmark’s drugs developer Neumirna Therapeutics (see here a previous post by BeBeez). Luis Pareras, a managing partner of Invivo Partners, and Thomas Thestrup, senior principal of Angelini Ventures, joined the company’s board of which are already part Milla Koistinaho and Henrik Klitgaard who founded the business in 2020 with Sakari Kauppinen and Lars Hellerung Christiansen. Neumirna will invest such resources in the development of its drugs.
US private equity AnaCap is close to acquiring Wefox Italy and its subsidiaries Wefox MGA and Wefox Services from troubled German insurtech Wefox Group for 70 million euros (see here a previous post by BeBeez).
